Track the NeuroBo Pharmaceuticals, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 20 September 2024 (Cession). Among the most active insiders: DONG-A ST CO., LTD. The full history is openly available.
22
Insider Decl.
n/a
Thresholds
€17m
2 ops.
Buy Volume
€1,378
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NeuroBo Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
30Σ signal
Buys €17m€1,378 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
NeuroBo Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It employs innovative approaches to enhance the quality of life for patients.